Literature DB >> 2076389

Influence of nifedipine on experimental arteriosclerosis.

A M Knorr1, S Kazda.   

Abstract

The nonhemodynamic actions of nifedipine and some other calcium antagonists are reviewed with regard to their relevance to the vasculoprotective and antiarteriosclerotic action of calcium antagonists. Nifedipine, and in order of declining potency, verapamil and diltiazem were shown to inhibit vascular myocyte proliferation and migration. Also, the incorporation of cholesteryl esters into macrophages or myocytes was inhibited by dihydropyridines and verapamil but not by diltiazem. The cholesterol and calcium contents were found to be lowered in the aortae of hypercholesterinemic rabbits treated chronically with dihydropyridine calcium antagonists. Replacement of damaged vascular endothelium and internal elastic lamina was seen in hypertensive Dahl-S rats after 6 weeks of antihypertensive treatment with nifedipine. In addition to their blood-pressure lowering action, these nonhemodynamic effects might be involved in the prevention and reversal of hypertensive vascular disease and neuropathologic symptoms observed after the treatment of hypertensive rats with nifedipine or other dihydropyridine calcium antagonists, since these therapeutic effects were also seen after blood-pressure neutral doses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076389     DOI: 10.1007/BF02018312

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  21 in total

1.  Plaque reversal with MgEDTA in experimental atherosclerosis: elastin and collagen metabolism.

Authors:  A Wartman; T L Lampe; D S McCann; A J Boyle
Journal:  J Atheroscler Res       Date:  1967 May-Jun

2.  The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation.

Authors:  J Nilsson; M Sjölund; L Palmberg; A M Von Euler; B Jonzon; J Thyberg
Journal:  Atherosclerosis       Date:  1985-12       Impact factor: 5.162

3.  Effects of anticalcifying and antifibrobrotic drugs on pre-established atherosclerosis in the rabbit.

Authors:  W Hollander; J Paddock; S Nagraj; M Colombo; B Kirkpatrick
Journal:  Atherosclerosis       Date:  1979-05       Impact factor: 5.162

4.  Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation.

Authors:  A Faggiotto; R Ross; L Harker
Journal:  Arteriosclerosis       Date:  1984 Jul-Aug

5.  Suppression of calcific fibrous-fatty plaque formation in rabbits by agents not affecting elevated serum cholesterol levels. The effect of thiophene compounds.

Authors:  C T Chan; H Wells; D M Kramsch
Journal:  Circ Res       Date:  1978-07       Impact factor: 17.367

6.  Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade.

Authors:  A Daugherty; D L Rateri; G Schonfeld; B E Sobel
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

7.  Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells. A possible mechanism for its antiatherogenic effect.

Authors:  O R Etingin; D P Hajjar
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

8.  Antiatherogenic activity of FR34235 (Nilvadipine), a new potent calcium antagonist. Effect on cuff-induced intimal thickening of rabbit carotid artery.

Authors:  A Nomoto; J Hirosumi; C Sekiguchi; S Mutoh; I Yamaguchi; H Aoki
Journal:  Atherosclerosis       Date:  1987-04       Impact factor: 5.162

9.  Cholesteryl ester synthesis in macrophages: stimulation by beta-very low density lipoproteins from cholesterol-fed animals of several species.

Authors:  R W Mahley; T L Innerarity; M S Brown; Y K Ho; J L Goldstein
Journal:  J Lipid Res       Date:  1980-11       Impact factor: 5.922

10.  Calcium dependency of aortic smooth muscle cell migration induced by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. Effects of A23187, nicardipine and trifluoperazine.

Authors:  J Nakao; H Ito; T Ooyama; W C Chang; S Murota
Journal:  Atherosclerosis       Date:  1983-03       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.